21 June 2011: Source: Nature
Animal studies show that a vaccine against prostate cancer can be effective. This is evidenced by an article in Nature. Here is the abstract of this study with some quotes from an article in advance about the same Meds cape study. Noteworthy that the researchers say that this way of immunotherapies would be applied to many patients kunen.
Source: Meds cape: click here to read the full article
Animal studies of a new human prostate cancer vaccine show that repeated intravenous infections can destroy prostate tumors in mice, without well-established adjuvant chemotherapy or radiation and with no apparent adverse effects ... ... ...
The vaccine was developed by inserting a cDNA library from healthy human prostate tissue into mutated viruses, which were then cultured vesicular stomatitis and given to test mice with established prostate tumors. The results showed that 9 intravenous infections cured more than 80% of the established tumors in the mice, without triggering autoimmunity.
"Nobody knows how many antigens the immune system can really see on tumor cells," senior author Richard Vile, PhD, said in a press statement. "By expressing all of these proteins in highly immunogenic viruses, we increased their visibility to the immune system. The immune system now thinks it is being invaded by the viruses, which are expressing cancer-related antigens that should be eliminated. "..........
New Approach Targets Tumor From Many Routes
Previous attempts to vaccinate against prostate and other types of detecting pre-cancerous tumors have been hampered by the inability of researchers to isolate, largely a sufficiently diverse and robust collection of antigens in tumor cells. Because of this, tumors often mutate and reestablish themselves in spite of the body's immune system. The use of viruses as vectors for cDNA libraries overcomes the difficulty of isolating tumor cells by giving the antigens in immune system a more complete picture of the detecting pre-cancerous invader.
This approach used doses of a vaccine that contained a library of DNA with multiple fragments of genes and, therefore, many possible antigens. This approach did not send the immune system into overdrive, which had been a concern. Instead, the range or DNA meant that the vaccine was able to target the tumour through many routes.
Importantly, the DNA library was harvested from the same organ as the tumor. This meant that the immune system self-selected the cancer antigens it respond to, and did not react against healthy parts of the body. The fact that The process of self-selection was triggered when the vaccine was injected intravenously means that the vaccine can be given systemically, obviating the need for tumor targeting.
TranslateApiException: AppId is over the quota : ID=3743.V2_Json.Translate.4D003684
